	US 12,419,892 B2
	Pharmaceutical compositions comprising nilotinib
Andreas Fischer, Uppsala (SE); and Thomas Andersson, Segeltorp (SE)
Assigned to XSPRAY PHARMA AB, Solna (SE)
Filed by XSPRAY PHARMA AB, Solna (SE)
Filed on Nov. 8, 2024, as Appl. No. 18/941,137.
Claims priority of provisional application 63/596,990, filed on Nov. 8, 2023.
Prior Publication US 2025/0144096 A1, May 8, 2025
Int. Cl. A61K 31/506 (2006.01); A61K 9/14 (2006.01); A61K 9/48 (2006.01)

CPC A61K 31/506 (2013.01) [A61K 9/146 (2013.01); A61K 9/4816 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01)]

20 Claims

1. A composition comprising:

(a) a particulate amorphous solid dispersion (ASD) comprising nilotinib free base and copovidone; and

(b) asborbic acid in admixture with the particular ASD;

wherein the nilotinib is present in an amount of from abuot 20% w/w to about 30% w/w of the particulate ASD; and

wherein the ascorbic acid is present in an amount of from about 0.5 to about 5 times the amount of nilotinib (weight to weight).